Dyslipidemia in CHB patients on TAF: Facts and Puzzles

Hung-Yao Lin¹, Tai-Chung Tseng¹-³

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. ²Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. ³Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

Correspondence and reprint requests to:
Dr. Tai-Chung Tseng
Assistant Professor, Department of Medical Research
National Taiwan University Hospital
1 Chang-Te St., Taipei 10002, TAIWAN
Tel.: 886-2-23123456 ext. 66144
Fax: 886-2-23825962
E-mail: tctsenghbv@gmail.com
Orcid ID: https://orcid.org/0000-0003-0420-8311

Running head: Dyslipidemia & TAF

Disclosure
H-Y, L. Declares no conflict of interest.
T-C. T. has served on speaker’s bureaus for Fujirebio, Bristol-Myers Squibb, and Gilead Sciences and received grant support from Gilead Sciences.
Most chronic hepatitis B (CHB) patients need to stay on indefinite nucleos(t)ide analogue (NA) to reduce hepatitis B virus (HBV)-related complications as HBV could only be contained but not cured by NA. Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are two potent NAs and TAF is favored over TDF due to less renal and bone toxicities. However, deterioration of lipid profile has been shown after switching from TDF- to TAF-containing antiretroviral regimens in HIV patients in both clinical trials and real-world data. Since dyslipidemia is associated with cardiovascular disease (CVD) and metabolic/non-alcoholic associated fatty liver disease, and the latter could increase HCC risks, it should be clarified whether TAF therapy alone deteriorates lipid profile in CHB patients.

In this study, Jeong et al. applied propensity score-matching to compare the changes of lipid profile among CHB patients receiving TAF or TDF, inactive CHB, and non-HBV infected control groups in a follow-up period of 48 weeks. The results showed a significant decrease of serum total cholesterol (TC) level in the TDF group when compared with TAF (156.7 ± 27.7 vs 176.3 ± 32.9, P < 0.001) and non-HBV infected (156.2 ± 28.3 vs 175.0 ± 29.5, P <0.001) group. In contrast, comparable lipid profiles were identified among TAF group, inactive CHB, and non-HBV infected control groups. The authors concluded that TAF is a lipid-neutral agent as the alterations of lipid profile were comparable between TAF and control groups. In contrast, TDF is potentially associated with lipid-lowering effect.

Jeong et al. further postulated that the higher circulating tenofovir (TFV) concentration in TDF users than that in TAF users might explain the results. Their theory was supported by another paper from Canada in which lower lipids were observed in TDF group when compared with the entecavir group in CHB patients. However, the underlying mechanism remains unclear.

Although this study shows that TAF may be lipid-neutral in CHB patients without dyslipidemia, several issues need to be addressed. First, the effect of TAF on CHB patients with dyslipidemia remains unknown as they were excluded in this study. In a retrospective, observational, multicenter study targeting HIV patients, no significant increment of TC level was found in TAF group if the patient had underlying hyperlipidemia. More studies are needed to address the issue. Nevertheless, physicians should keep a close eye on patients with lipid levels near the upper limit of normal when switching from TDF to TAF. Second, even if switching from TDF to TAF causes more patients developing dyslipidemia, there are multiple potent lipid-lowering agents available. The benefit of lipid-lowering effect of TDF should not outweigh the risks of well-documented bone and kidney adverse events.

In summary, this well-designed study indicates that TAF itself could be a lipid-neutral rather than a lipid-increasing agent. Physicians should monitor the lipid
profile more closely in their patients when switching their TDF with TAF. Future studies with longer follow-up periods and broader patient inclusion criteria to explore CV outcomes, together with the findings of this research, may impact the way CHB patients are managed.
Reference

3. Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med 2018;19:724-733.